Pfizer, Moderna shares plunge on report that Trump officials plan to link 25 child deaths to COVID vaccine

Core Viewpoint - Shares of Pfizer and Moderna experienced declines of 3.9% and 7.4%, respectively, following reports that the Trump administration intends to link the deaths of 25 children to COVID vaccines, which may influence vaccine access and costs [1][8]. Group 1: Impact on Vaccine Companies - The planned presentation by Trump health officials could affect the perception and market performance of Pfizer and Moderna, as it may lead to changes in vaccine recommendations and insurance coverage [1][8]. - The report indicates that the deaths were sourced from the Vaccine Adverse Event Reporting System (VAERS), which is known for containing unverified reports of vaccine side effects [2][3]. Group 2: Regulatory and Advisory Context - The upcoming meeting of the vaccine advisory panel is critical, as it will determine whether insurers are required to cover the vaccines and the willingness of pharmacies and doctors to administer them [8]. - Health and Human Services Secretary Robert F. Kennedy Jr. has made significant changes to the vaccine panel, replacing its members with his own selections, which may influence future vaccine policy [8][13]. Group 3: Public Health Recommendations - The American Academy of Pediatrics continues to recommend annual COVID vaccinations for children aged 6 to 23 months and asserts that the vaccines are safe and effective [14]. - In contrast, Kennedy has directed health officials to cease recommending vaccinations for healthy children, suggesting that only high-risk individuals or those over 65 should receive them [9][13].